222 related articles for article (PubMed ID: 36765089)
21. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors.
Zindy F; Uziel T; Ayrault O; Calabrese C; Valentine M; Rehg JE; Gilbertson RJ; Sherr CJ; Roussel MF
Cancer Res; 2007 Mar; 67(6):2676-84. PubMed ID: 17363588
[TBL] [Abstract][Full Text] [Related]
22. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.
Zhang L; He X; Liu X; Zhang F; Huang LF; Potter AS; Xu L; Zhou W; Zheng T; Luo Z; Berry KP; Pribnow A; Smith SM; Fuller C; Jones BV; Fouladi M; Drissi R; Yang ZJ; Gustafson WC; Remke M; Pomeroy SL; Girard EJ; Olson JM; Morrissy AS; Vladoiu MC; Zhang J; Tian W; Xin M; Taylor MD; Potter SS; Roussel MF; Weiss WA; Lu QR
Cancer Cell; 2019 Sep; 36(3):302-318.e7. PubMed ID: 31474569
[TBL] [Abstract][Full Text] [Related]
23. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.
Brown HG; Kepner JL; Perlman EJ; Friedman HS; Strother DR; Duffner PK; Kun LE; Goldthwaite PT; Burger PC
J Neuropathol Exp Neurol; 2000 Oct; 59(10):857-65. PubMed ID: 11079775
[TBL] [Abstract][Full Text] [Related]
24. N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma.
Kuzuoglu-Ozturk D; Aksoy O; Schmidt C; Lea R; Larson JD; Phelps RRL; Nasholm N; Holt M; Contreras A; Huang M; Wong-Michalak S; Shao H; Wechsler-Reya R; Phillips JJ; Gestwicki JE; Ruggero D; Weiss WA
Cancer Res; 2023 Jan; 83(1):130-140. PubMed ID: 36264168
[TBL] [Abstract][Full Text] [Related]
25. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma.
Browd SR; Kenney AM; Gottfried ON; Yoon JW; Walterhouse D; Pedone CA; Fults DW
Cancer Res; 2006 Mar; 66(5):2666-72. PubMed ID: 16510586
[TBL] [Abstract][Full Text] [Related]
26. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
27. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
28. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
[TBL] [Abstract][Full Text] [Related]
29. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
[TBL] [Abstract][Full Text] [Related]
30. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Qin N; Paisana E; Langini M; Picard D; Malzkorn B; Custódia C; Cascão R; Meyer FD; Blümel L; Göbbels S; Taban K; Bartl J; Bechmann N; Conrad C; Gravemeyer J; Becker JC; Stefanski A; Puget S; Barata JT; Stühler K; Fischer U; Felsberg J; Ayrault O; Reifenberger G; Borkhardt A; Eisenhofer G; Faria CC; Remke M
Neuro Oncol; 2022 Sep; 24(9):1509-1523. PubMed ID: 35307743
[TBL] [Abstract][Full Text] [Related]
32. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic MYC amplifies mitotic perturbations.
Littler S; Sloss O; Geary B; Pierce A; Whetton AD; Taylor SS
Open Biol; 2019 Aug; 9(8):190136. PubMed ID: 31455158
[TBL] [Abstract][Full Text] [Related]
34. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.
Binning MJ; Niazi T; Pedone CA; Lal B; Eberhart CG; Kim KJ; Laterra J; Fults DW
Cancer Res; 2008 Oct; 68(19):7838-45. PubMed ID: 18829539
[TBL] [Abstract][Full Text] [Related]
35. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
36. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
37. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
38. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma.
Veo B; Danis E; Pierce A; Wang D; Fosmire S; Sullivan KD; Joshi M; Khanal S; Dahl N; Karam S; Serkova N; Venkataraman S; Vibhakar R
Cell Rep; 2021 Apr; 35(4):109013. PubMed ID: 33910002
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
